Diet / Gut Microbiome Interaction and Influence on Inflammatory Disease in HIV Patients
NCT ID: NCT02610374
Last Updated: 2022-01-21
Study Results
The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.
Basic Information
Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.
COMPLETED
NA
90 participants
INTERVENTIONAL
2016-03-31
2020-03-31
Brief Summary
Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.
Related Clinical Trials
Explore similar clinical trials based on study characteristics and research focus.
Factors Mediating Gut Microbiota Dysbiosis and Metabolic Disease in HIV Patients.
NCT02258685
Fecal Microbiota Transplantation in HIV
NCT02256592
Effectiveness of Gut Microbiota-targeted Dietary Intervention Among HIV-infected Patients
NCT06279819
Effectiveness of Gut Microbiota-targeted Diatery Intervention Among People Living With HIV
NCT06498401
HIV and Changes in the Gut Microbiome After Changes in Antiretroviral Therapy (ART)
NCT06100211
Detailed Description
Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.
Conditions
See the medical conditions and disease areas that this research is targeting or investigating.
Study Design
Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.
RANDOMIZED
PARALLEL
OTHER
NONE
Study Groups
Review each arm or cohort in the study, along with the interventions and objectives associated with them.
Cohort A
HIV-positive individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
Agrarian Diet
A diet higher in carbohydrates and lower in fats and sugars
Western-type Diet
A diet higher in fats and lower in carbohydrates
Cohort B
HIV-negative high-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
Agrarian Diet
A diet higher in carbohydrates and lower in fats and sugars
Western-type Diet
A diet higher in fats and lower in carbohydrates
Cohort C
HIV-negative low-risk individuals will be randomized to receive either an Agrarian diet or a Western-type diet for 4 weeks.
Agrarian Diet
A diet higher in carbohydrates and lower in fats and sugars
Western-type Diet
A diet higher in fats and lower in carbohydrates
Interventions
Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.
Agrarian Diet
A diet higher in carbohydrates and lower in fats and sugars
Western-type Diet
A diet higher in fats and lower in carbohydrates
Eligibility Criteria
Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.
Inclusion Criteria
* Documentation of HIV-1 infection defined as a positive antibody test or plasma HIV-1 RNA (ribosomal ribonucleic acid).
* Treated with ART (minimum of three antiretroviral drugs in regimen) for at least 12 months with no changes in antiretroviral drugs over the past 6 months
* Plasma HIV-1 RNA ≤ 50 copies/mL in the preceding 6 months.
* HIV-negative cohorts (Cohort B and C)
* Documentation of a negative HIV-1 antibody test
* All Cohorts
* Age 18 to 65 years
* Body mass index between 21-29 kg/m2 (non-obese)
* Stable weight for at least 3 months (≤15% change in body weight)
* Negative pregnancy test (if female)
Exclusion Criteria
* Active chronic infection such as hepatitis B or C or an active malignancy that requires systemic chemotherapy.
18 Years
65 Years
ALL
Yes
Sponsors
Meet the organizations funding or collaborating on the study and learn about their roles.
University of Colorado, Denver
OTHER
Responsible Party
Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.
Principal Investigators
Learn about the lead researchers overseeing the trial and their institutional affiliations.
Catherine Lozupone, PhD
Role: PRINCIPAL_INVESTIGATOR
University of Colorado, Denver
Locations
Explore where the study is taking place and check the recruitment status at each participating site.
University of Colorado Denver
Aurora, Colorado, United States
Countries
Review the countries where the study has at least one active or historical site.
Other Identifiers
Review additional registry numbers or institutional identifiers associated with this trial.
15-1692
Identifier Type: -
Identifier Source: org_study_id
More Related Trials
Additional clinical trials that may be relevant based on similarity analysis.